Simple Summary The aim of our study is to provide a wide perspective on the available
literature data on the immune landscape of breast cancers, focusing on TILs and PD-L1 …

Breast cancer (BC), one of the most widespread and devastating diseases affecting women
worldwide, presents a significant public health challenge. This review explores the emerging …

The large majority of patients with HER2-positive metastatic breast cancer (MBC) will
eventually develop resistance to anti-HER2 therapy and die of this disease. Despite …

Inflammatory breast cancer (IBC) is the most aggressive and fatal clinical presentation of
breast cancer. Despite the term “inflammatory”, based on the clinical presentation, IBC is …

Triple-negative breast cancer (TNBC) is an invasive and persistent subtype of breast cancer
that is likely to be resistant to conventional treatments. The rise in immunotherapy has …

Metaplastic breast cancer (MpBC) is a rare and aggressive subtype of breast cancer, with
data emerging on prognostic factors and survival prediction. This study aimed to develop …

Radiation therapy (RT) has long been fundamental for the curative treatment of breast
cancer. While substantial progress has been made in the anatomical and technological …

Breast cancer (BC) is the most common neoplasm in women worldwide and one of the
leading causes of female death. The triple-negative subtype, characterized by the absence …

Because of the limited data from clinical trials, no conclusions about the activity of ICIs in IBC
can be drawn. Ongoing clinical trials are assessing many promising ICI-based combination …

Background There are significant correlations between the levels of tumor infiltrating
lymphocytes (TILs) and the prognosis of primary breast cancer. While little is known about …